source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
- Greenwich Rx voluntarily recalls compounded sterile products over sterility concernsGreenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, announced a voluntary nationwide recall of certain compounded sterile product lots that are still within their beyond-use dates.…